Cayman 2,3,5-Triacetyluridine

2’,3’,5’-Triacetyluridine is a prodrug of uridine (Item No. 20300).¹ It is more lipid soluble than uridine and resistant to degradation by uridine phosphorylase. It is cleaved by plasma esterases in vivo to release uridine. 2’,3’,5’-Triacetyluridine (6% in the diet) decreases neurodegeneration in the piriform cortex and striatum, as well as reduces the amount of huntingtin-positive aggregates and increases BDNF protein levels in the piriform cortex in a transgenic mouse model of Huntington’s disease.² It also improves rotarod performance and increases survival in transgenic mouse models of Huntington’s disease. 2’,3’,5’-Triacetyluridine reverses toxicity and increases survival in a mouse model of dihydropyrimidine dehydrogenase (DPD) deficiency-induced 5-fluorouracil (5-FU; Item No. 14416) overdose when used at a concentration of 2,000 mg/kg three times per day beginning within 24 hours of 5-FU administration.³ Formulations containing 2’,3’,5’-triacetyluridine have been used in the treatment of hereditary orotic aciduria and of overdose or life-threatening toxicity due to flurouracil or capecitabine.

WARNING This product is not for human or veterinary use.